Trump’s Most-Favored-Nation Drug Pricing is Rewiring Traditional R&D Models

11th September, 2025 | 15:12 BST

Join us for the latest edition of 𝐨𝟐𝐡 𝐂𝐡𝐚𝐢𝐓𝐢𝐦𝐞 𝐖𝐞𝐛𝐢𝐧𝐚𝐫, where industry thought leaders delve into the return of MFN drug pricing and its impact on biotech innovation, strategic partnerships, and investment planning. This thought-provoking discussion features a distinguished panel: Hilary Schultz (Founder & CEO, Persephoni BioPartners), Shreefal Mehta (Member, Research and Entrepreneurial Advisory Committee, Department of Biotechnology, Government of India – BIRAC), and Mahesh Narayanan (CEO & Co-founder, MatchPlay), chaired by Sunil Shah, Co-founder of o2h Discovery.



Together, the panel explores how MFN policy could reshape global R&D strategies, shift funding priorities, and influence where clinical trials are conducted. With perspectives spanning biotech entrepreneurship, public policy, and early-stage investing, this session delivers timely insight for biotech leaders, investors, and innovators navigating a rapidly evolving global landscape.